Enfortumab vedotin is an antibody-drug conjugate designed for the treatment of cancer expressing Nectin-4.
Enfortumab refers to the monoclonal antibody part.
Vedotin refers to the payload drug and the linker.
Trade name Padcev.
Routes of administration IV
Common side effects: fatigue, peripheral neuropathy, decreased appetite, rash, alopecia, nausea, altered taste, diarrhea, dry eye, pruritus, and dry skin.
The initial clinical trial enrolled 125 patients with locally advanced or metastatic urothelial cancer who received prior treatment with a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy.
The overall response rate, was 44%, with 12% having a complete response and 32% having a partial response.
The median duration of response was 7.6 months.